The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

  ()
This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

  ()
With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts.

Nine Stocks Expert Says Should Pique Your Interest

Contributed Opinion
  ()
Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on.

Clean Nuclear Med Tech With Quantum Blue Sky

Contributed Opinion
  ()
With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention.

Biopharma Gains Two Cancer Cell Therapy Programs and a Target Price 10 Times Current

Research Report
  ()
This developer of cancer immunotherapies will take possession of these clinical-stage assets in a transaction with GSK and subsequently advance them toward approval, noted a ROTH Capital Partners report.

Potential ROI With German Biopharma Co. Notable

Research Report
  ()
This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report.

Expert Says Buy Pharma Co. Stock 'as Soon as Possible'

Contributed Opinion
  ()
Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy it.

Biopharma Co. Shows Large Potential Return

Research Report
  ()
Palatin Technologies Inc.'s third-party clinical trial of Vyleesi in women with hypoactive sexual desire disorder was just published in the Journal of Clinical Investigation, and the biopharma offers investors significant potential return, noted an H.C. Wainwright & Co. report.

Biotech Co.'s Target Price Over Three Times Current

Research Report
  ()
Expanded interim data from the Phase 2 trial of this biotech's lead asset PDS0101 in HPV16-associated cancers are consistent with previously reported results from the same study. Read more to discover why H.C Wainright & Co. believes this stock is a Buy with a target price over three times the current.

Biopharma Co. Partners With Merck for Combo Drug Trial

Research Report
  ()
With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted an H.C. Wainwright & Co. report.

Chen Reveals His Picks for Last Quarter

  ()
Asset manager Chen Lin's picks for the home stretch of 2022 include several biotechs and some precious metals companies.

Biotech Co.'s Drug Showing 'Early Signs of Benefit'

Research Report
  ()
With this upcoming analysis, the board will determine whether the Phase 2b/3 trial may continue to completion, noted a ROTH Capital Partners report.

Showing Results: 26 to 50 of 115 Prev Next